A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable.

Burnett, Alan Kenneth, Baccarani, M., Johnson, Peter, Yin, John, Sounders, Andrew, Russell, Nigel and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2006. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood -New York- 108 (11) , 130A-130A.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	48th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 09-12, 2006
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	24 Oct 2022 11:55
URI:	https://orca.cardiff.ac.uk/id/eprint/49733

Actions (repository staff only)

Edit Item